临床特征和诊断和治疗肌缩性侧面硬化症的进展
Dongxiang Yuan1, Shishi Jiang1, Renshi Xu1
1Department of Neurology, Jiangxi Provincial People's Hospital; The Clinical College of Nanchang Medical College; The First Affiliated Hospital of Nanchang Medical College; Xiangya Hospital of Center South University, Jiangxi Hospital; National Regional Center for Neurological Disease, Honggutan District, Nanchang, Jiangxi Province, China.
Annals of medicine
|December 3, 2024
概括
肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病. 本综述涵盖了ALS流行病学,遗传学,临床特征以及诊断和治疗方面的进展,以改善患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医学研究 医学研究
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性,致命的神经退行性疾病,影响中枢神经系统.
- 目前对ALS的预测仍然具有挑战性,尽管进行了广泛的研究.
- 了解ALS的多面性质对于治疗开发至关重要.
研究的目的:
- 为了提供关于肌缩侧面硬化症 (ALS) 的全面概述.
- 详细介绍ALS的流行病学,遗传基础和临床表现.
- 审查最近在ALS诊断标准和治疗策略方面的进展.
主要方法:
- 关于ALS现有研究的文献综述.
- 综合有关临床特征,遗传学和流行病学的信息.
- 分析诊断标准和治疗方式的进展情况.
主要成果:
- ALS的特点是特定的流行病学模式和遗传因素.
- 病变的临床表现是多样化的,需要准确的诊断.
- 新的诊断标准和新兴的治疗方法对ALS管理有希望.
结论:
- 对ALS病变的持续研究是必不可少的.
- 诊断准确度的提高可以促进早期干预.
- 加快开发和实施有效的ALS治疗方法是首要任务.
相关概念视频
Parkinson's Disease: Overview
479
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
479
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Cross-bridge Cycle
116.9K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
116.9K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K


